Back to top

dna-sequencing: Archive

Zacks Equity Research

FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23%

FibroGen (FGEN) falls 22.7% as its late-stage study of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy fails to meet the primary endpoint.

JNJNegative Net Change SRPTPositive Net Change CORTPositive Net Change FGENPositive Net Change

Zacks Equity Research

Axcella (AXLA) Up on Patent Grant for Long Covid Fatigue Drug

Axcella (AXLA) shares surge 299% after the company secures a methods-of-use patent for its lead candidate, AXA1125, which is currently under development to treat fatigue associated with Long Covid.

DVAXPositive Net Change JNJNegative Net Change CORTPositive Net Change

Sanghamitra Saha

Oncology Market's Huge Potential Puts These Stocks in Focus

The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.

REGNPositive Net Change AZNPositive Net Change NVSPositive Net Change MRKPositive Net Change

Zacks Equity Research

Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why

Armata Pharma (ARMP) stock skyrockets 130% in a month due to encouraging progress of the company's pathogen-targeting natural and synthetic phage candidates.

DVAXPositive Net Change JNJNegative Net Change CORTPositive Net Change ARMPPositive Net Change